BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

DOW PHARMACEUTICAL SCIENCES NAMES DAVID W. OSBORNE VICE PRESIDENT OF PRODUCT DEVELOPMENT   
PETALUMA, CA – September 22, 2003: Dow Pharmaceutical Sciences, Inc., a company specializing in the development of topical pharmaceutical products, is pleased to announce the appointment of Dr. David W. Osborne as Vice President of Product Development. Dr. Osborne will oversee formulations, process development and skin biology at Dow Pharmaceutical Sciences.  
 
David brings to Dow Pharmaceutical Sciences more than 18 years of experience in developing dermatological and other topical products. Prior to joining Dow Pharmaceutical Sciences, Dr Osborne was Vice President of the Dermatology Division at Atrix Laboratories, Inc. Earlier in his career he was Vice President of Research and Development at ViroTex Corporation, a topical drug delivery company. Dr. Osborne’s extensive drug-development experience also includes positions with Merck and The Upjohn Company.  
 
Dr. Osborne has been awarded more than 20 patents and two federal grants. He co-authored a book on topical drug formulations and has authored or coauthored more than 40 articles and publications.  
 
“David’s knowledge and extensive experience adds a new dimension in our ability to develop new topical products” said Bhaskar Chaudhuri, PhD, President and Chief Executive Officer of Dow Pharmaceutical Sciences.  
 
David holds a PhD in physical chemistry from the University of Missouri-Rolla and a BS in chemistry from Southwest Missouri State University.  
 
Dow Pharmaceutical Sciences develops topical products for pharmaceutical and biotechnology clients. Services include formulation development and optimization; skin-permeation and SUPAC studies; analytical and stability testing; and manufacturing, labeling and distribution of clinical-trial materials. Dow also provides regulatory, non-clinical and clinical services required to take topical products through FDA approval. This includes phase I-III trials at Dow’s two clinical sites.  
 
For more information please visit www.dowpharmsci.com   
 
# # #  
Contact: Steven R. Smith  
Vice President, Marketing & Business Development  
1330A Redwood Way, Petaluma, CA 94954  
707-665-4672  
ssmith@dowpharmsci.com
   

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.